.svg)
Review our pipeline for a detailed overview of our key initiatives and their status in the development and testing process.
MVMD is here to change the world. To push the boundaries of science and exploration. To go beyond possible… and reach for the stars into the universe of all things impossible.
Our patented technologies are embedded across critical projects that are focused on doing more with less, making world-class drugs and vaccines more accessible, and driving significant inefficiencies and costs out of the legacy manufacturing and distribution systems.
Review our product pipeline below for a detailed overview of our key initiatives and related status.
Program
Tech
Market
Value Proposition
Macrocyclic Lactone Solubilization
Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.
Quicksome™
Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options.
Quicksol™
Drug, Human Therapeutic, Animal Parasitic
Significant improvement over current oral form ivermectin drug –waterless oral dissolve, dramatically quicker onset, zero decline over extended periods in the body, less variability, requires a fraction of the Ivermectin API, uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), leading candidate for human injection and sublingual applications, broader husbandry and companion animal applications based on low viscosity. Implications for COVID-19 viral clearance, prophylactic, and broader applications for the elimination of malaria and dengue.
2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Completed
Completed
MVMD has the best pharmacokinetic data for Ivermectin in the world with broad implications for both human and animal health. Pre-clinical key findings:
• MVMD’s solubility technology delivered 800% increase in bio availability through intramuscular (IM) injection and 500% increase in bio availability through sublingual compared to oral tablets.
• MVMD’s IM injection reaches TMAX (the time to reach the maximum concentration of Ivermectin in the body) at 15 minutes compared to current commercial oral and subcutaneous forms which take between 6 and 36 hours and is well documented. The Company’s sublingual strips had a TMAX of1 hour, a 600% increase over oral tablets.
• Both MVMD applications showed zero decline in CMAX (peak serum concentration that a drug achieves) over an extended timeframe of 12 hours, with gradual decline over 96 hours (vs 36 hours for oral tablet) almost 3x extended clearance - a very significant indication over oral and subcutaneous forms.
• Both MVMD applications show minimal pharmacokinetic variability, with IM injection at zero percent variability and sublingual strips at 5% variability compared to40% variability for oral tablets. Variability contributes to the potential for adverse effects or not achieving the required therapeutic index.
Completed
Completed
Bio Safety Level 4 (“BSL-4”) lab study of COVID-19 viral clearance in transgenic mice designed to prove the superiority of the Company’s solubilized Ivermectin technology versus commercially available oral form in speed and efficacy of viral clearance. Demonstration of how solubility technology applied to the Ivermectin drug can be applied as a broad therapeutic to immediately treat COVID-19, as well as its role in stopping the deadly spread of future pandemics, including a world’s first as an injectable Ivermectin format for emergency front line usage as well as a rapid dissolve tablet that is administered for prevention like vitamin C around the world.
There are less than thirty BSL-4 facilities in the world capable of performing this study and it is not unusual for projects to take up to three years to schedule. The Company was able to demonstrate the significance of its patented solubilized Ivermectin technology through its presentation of the superior pharmacokinetic data documented from two previously completed pre-clinical trials.
This study will be the first of its kind ever conducted with human grade solubilized Ivermectin anywhere in the world and its design was led by the Company’s key scientific advisor,
Dr. John Clements.
Completed
Completed
In progress
In progress
In progress
Pending
In Progress
In Progress
Oncology
Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.
Quicksome™
Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options.
Quicksol™
Oncology
Ivectosol™ being tested to target certain cancers to pursue novel human intratumoral injection and intravenous infusion.
2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Completed
Completed
Study will test the effectiveness of Ivectosol™ combined with checkpoint inhibitor that would be equivalent to either OPDIVO or Keytruda for disease progression and complete response rate. Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor and intratumoral IVM + checkpoint inhibitor.
In Progress
In Progress
In Progress
Study will test the effectiveness of Ivectosol™ intratumorally combined with checkpoint inhibitor for disease progression and complete response rate. Arms in the study will look at single checkpoint inhibitor, oral IVM + check pointinhibitor and intratumoral IVM + checkpoint inhibitor
In Progress
In Progress
In Progress
Study will test the effectiveness of Ivectosol™ intratumorally combined with checkpoint inhibitor for disease progression and complete response rate. Arms in the study will look at single checkpoint inhibitor, oral IVM + checkpoint inhibitor, intratumoral IVM + checkpoint inhibitor, navalbine + intratumoral IVM
In Progress
In Progress
In Progress
Dose Sparing Adjuvant
Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.
Quicksome™
Dose Sparing Adjuvant
Patent-Pending Porous Aluminum Nanostructure Adjuvant has high surface area for vaccine-antigen binding to provide dose sparing advantages with long-term stability in aqueous media, and greater stability in harsh environments.
Adjuvant
Vaccine
Use less vaccine per dose, cost reduction, increase vaccine output, facilitate mucosal and herd immunity, long-term stability in aqueous media, promote greater stability in harsh environments, inform significant dose sparing applications across hundreds of vaccines, key to global disease eradication
2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Completed
Completed
Completed
The study will compare existing Alhydrogel adjuvant to the Company’s recently invented stable nano-particulate adjuvant by both intramuscular injection and intradermal injection immunization, evaluating the antibody responses following vaccination with fractional doses of IPV comparing delivery types with IPV alone or adjuvanted.
In Progress
In Progress
Pending
Pending
Cold Chain
Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.
Quicksome™
Dose Sparing Adjuvant
Patent-Pending Porous Aluminum Nanostructure Adjuvant has high surface area for vaccine-antigen binding to provide dose sparing advantages with long-term stability in aqueous media, and greater stability in harsh environments.
Adjuvant
Vaccine
Enable distribution outside of cold chain, use less vaccine per dose, cost reduction, increase vaccine output, key to global disease eradication
2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Completed
Completed
Completed
Completed
Completed
In Progress
Pending
Pending
Pending
Expanded Ivermectin Applications
Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.
Quicksome™
Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options.
Quicksol™
Human Parasitic, Therapeutic, Animal Parasitic
Enhanced treatment options and effectiveness across broad ectoparasitic applications.
2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Pending
Pending
Pending
Selamectin
Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.
Quicksome™
Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options.
Quicksol™
Human Parasitic, Therapeutic, Animal Parasitic
No current human forms – solubilized pursuit would open up applications similar to MVMD’s work with ivermectin – waterless oral dissolve, inhalable, or injectable, dramatically quicker onset, zero decline over extended periods in the body, less variability, requires a fraction of the API, uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), leading candidate for human injection and sublingual applications, broader husbandry and companion animal applications based on low viscosity. Pursuing implications for Tuberculosis treatment.
2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Completed
Pending
Pending
Pending
Pending
Pending
Sublingual Pharmaceutical
Applications across human pharmaceutical and vaccine space
Stable delivery, waterless oral dissolve, quicker onset, precise dosing, reduced variability, dose sparing, needleless administration, pain elimination, reduced risk of infection and common site injection reactions, reduced complexities for medically supervised administration.
2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Completed
Completed
Completed
Pending
Pending
Sublingual Nutraceutical
Applications across human nutraceutical
Stable delivery, waterless oral dissolve, quicker onset, precise dosing, reduced variability, dose sparing, needleless administration, easy to use formats.
2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Completed
Completed
In Progress
Completed
Insulin
Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.
Quicksome™
Human insulin drug
Stable sublingual delivery, waterless oral dissolve, rapid onset, precise dosing, reduced variability, needleless administration, easy to use format.
2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Completed
Completed
In Progress
Pending
Pending
Pending
Sublingual Cannabis
Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.
Quicksome™
Applications across cannabis
Stable delivery, waterless oral dissolve, quicker onset, precise dosing, reduced variability, dose sparing.
